Pictus Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 226.86%
- Profit Growth 99.15%
- Ebitda 193.79%
- Net Worth -0.91%
- Total Assets 44.63%
About Pictus Pharmaceutical
Pictus Pharmaceutical Private Limited (PPPL) is a Private Limited Indian Non-Government Company incorporated in India on 31 October 2017 (Seven years and three months 27 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Pramod Pal, Ashish Shukla, and Rahul Dubey serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999DL2017PTC325490
- Company No.
325490
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Oct 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
What products or services does Pictus Pharmaceutical Private Limited offer?
Pictus Pharmaceutical Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Multivitamin Syrup & Drops.
Who are the key members and board of directors at Pictus Pharmaceutical?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pramod Pal  | Director | 01-Jul-2021 | Current |
| Ashish Shukla | Director | 30-Nov-2019 | Current |
| Rahul Dubey | Director | 30-Nov-2019 | Current |
Financial Performance of Pictus Pharmaceutical.
Pictus Pharmaceutical Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 226.86% increase. The company also saw a substantial improvement in profitability, with a 99.15% increase in profit. The company's net worth dipped by a decrease of 0.91%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pictus Pharmaceutical?
In 2023, Pictus Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Pictus Pharmaceutical?
Unlock and access historical data on people associated with Pictus Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pictus Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pictus Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
